Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics issues time-based RSU and stock option inducement awards to eight new hires under its 2025 Inducement Equity Plan.

Rhea-AI Summary

Entrada Therapeutics (TRDA) granted equity inducement awards to eight newly hired non-executive employees under its 2025 Inducement Equity Plan, effective September 1, 2026.

The awards comprise an aggregate of 61,365 RSUs and options to purchase 19,425 shares of common stock, with an exercise price of $7.07 per share, equal to the closing price on August 31, 2026. The Compensation Committee approved these grants as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

Options vest 25% on the first anniversary of the vesting commencement date and 75% in 36 equal monthly installments thereafter, fully vesting on the fourth anniversary, subject to continued employment. RSUs vest 25% after one year and 6.25% quarterly on March 1, June 1, September 1 and December 1, subject to continuous service, all under the plan and award agreements.

Market Context

On June 01, the earlier inducement-grant announcement was followed by a -3.91% 24-hour reaction, pro...

Analysis

On June 01, the earlier inducement-grant announcement was followed by a -3.91% 24-hour reaction, providing a company-specific comparison. The current award scale and vesting schedule remain central, while recent insider Net Selling is a relevant risk factor.

Key Figures

Restricted stock units: 61,365 RSUs Option shares: 19,425 shares Recipients: 8 newly-hired non-executive employees +4 more

7 metrics

Restricted stock units 61,365 RSUs Granted to newly hired employees

Option shares 19,425 shares Shares underlying inducement options

Recipients 8 newly-hired non-executive employees Inducement grants

Option exercise price $7.07 per share Equal to the August 31, 2026 closing price

Grant effective date September 1, 2026 Inducement Plan grants

Option vesting 25% at one year; 75% in 36 monthly installments Subject to continued employment

RSU vesting 25% at one year; 6.25% quarterly thereafter Subject to continuous service

Historical Context

5 past events · Latest: Aug 05 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 05	2Q26 earnings report	Negative	-2.5%	Lower collaboration revenue and net loss accompanied cash runway into third quarter 2027.
Jun 02	Dose escalation update	Positive	-3.9%	Committee recommended a 10 mg/kg Cohort 2 dose after reviewing eight participants.
Jun 01	Inducement equity grants	Negative	-3.9%	Company granted 18,600 RSUs to three newly hired non-executive employees.
May 07	1Q26 earnings report	Positive	-57.3%	Positive topline DMD data accompanied quarterly results and additional planned readouts.
May 07	Phase 1/2 clinical data	Positive	-57.3%	Cohort 1 reported favorable safety and biomarker changes, but juvenile pharmacokinetics were lower.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The stock's five recent reactions were negative, with divergence on three positive clinical or safety announcements and alignment on two negative or issuance-related events.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"The Company granted an aggregate of 61,365 restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company’s common stock to eight newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026. The options have an exercise price of $7.07 per share, which is equal to the closing price of the Company's common stock on August 31, 2026. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the vesting commencement date and thereafter the remaining 75% will vest in thirty-six equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the vesting commencement date, in each case, subject to each employee’s continued employment with the Company through each vesting date. One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quarterly thereafter on each subsequent vesting date, with such vesting dates of March 1, June 1, September 1 and December 1 of each subsequent year, in each case, subject to each employee’s continuous service with the Company through each vesting date. The options and RSUs are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2025 and the terms and conditions of award agreements covering the grants.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor Contact
Doug Snow
Head of Investor Relations
dsnow@entradatx.com

FAQ

What equity inducement awards did Entrada Therapeutics (TRDA) grant in September 2026?

Entrada Therapeutics granted an aggregate of 61,365 restricted stock units and options to purchase 19,425 shares of common stock to eight newly hired non-executive employees, effective September 1, 2026, under its 2025 Inducement Equity Plan.

What is the exercise price of the new Entrada Therapeutics (TRDA) stock options?

The newly granted options have an exercise price of $7.07 per share, which equals the closing price of Entrada Therapeutics common stock on August 31, 2026.

How do the stock options granted by Entrada Therapeutics (TRDA) vest for new employees?

For each employee, 25% of the option shares vest on the one-year anniversary of the vesting commencement date. The remaining 75% vest in 36 equal monthly installments, so the options fully vest on the fourth anniversary, subject to continued employment.

What is the vesting schedule for the RSUs granted by Entrada Therapeutics (TRDA)?

For the RSUs, 25% vest on the one-year anniversary of the vesting commencement date. Thereafter, 6.25% vest quarterly on March 1, June 1, September 1 and December 1 each year, subject to the employee’s continuous service.

Under which plan were the new Entrada Therapeutics (TRDA) inducement grants made?

The RSUs and stock options were granted under the company’s 2025 Inducement Equity Plan, which was approved by the Board of Directors in March 2025, and are subject to related award agreements.

Why were these Entrada Therapeutics (TRDA) equity awards structured as inducement grants?

The Compensation Committee approved the grants as a material inducement to the new employees’ entry into employment with Entrada Therapeutics, in accordance with Nasdaq Listing Rule 5635(c)(4).